Peer Review History
| Original SubmissionSeptember 7, 2020 |
|---|
|
PONE-D-20-28091 A profession in danger: Stakeholders’ perspectives on supporting the pharmacy profession in Lebanon PLOS ONE Dear Dr. Hijazi, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Nov 15 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Vijayaprakash Suppiah, PhD Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please include additional information regarding the qualitative interview guide used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed an interview guide as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. 3. In the Methods, please discuss whether and how the questionnaire was validated and/or pre-tested. If this did not occur, please provide the rationale for not doing so. 4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: N/A Reviewer #2: N/A ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: I think this is an interesting paper. The surplus of pharmacists is a troubling issue in many countries, including but not limited to Lebanon. This issue - especially the details of the mechanism by which market and policy forces may alleviate this surplus - have not been fully explored in the literature. Being a purely qualitative study, the transparency of the study's details are especially crucial in determining whether the study is of sufficient technical and rigorous merit to warrant publication. Many of these details are missing. I will note a few major issues below, noting that the list is not exhaustive. 1. What is the distribution of degrees awarded between the B.S. and the Pharm.D. degree each year? Are these scope of practice differences? Is the PharmD exclusively intended to work in institutional or other advanced practice settings? We need to know whether the surplus of pharmacists is a function of structural academic characteristics before it is possible to interpret the results of your analysis.We also need to know more about the specific clinical roles of a pharmacist - what is in place currently versus the aspirations of the profession as a whole. 2. The study also consistently posits a clausus as a means to address the surplus. Would such a clausus violate antitrust or anti-collusion laws in Lebanon? Are there alternative policy or market responses that could be considered as viable responses? By including this discussion in the introduction (in the manner in which it is introduced) it potentially biases the reader towards only one of many responses. 3. On page 6, why would robberies contribute to the over-supply of pharmacists? Would it not lead to the opposite effect? Also, the authors note that pharmacists trained outside of Lebanon contribute to the surplus of pharmacists. From where do the primarily originate? Do Lebanese trained pharmacists have the ability to practice internationally? If so, where can they practice? One cannot discuss one side of the labor market without addressing the other. 4. More details are necessary to justify the research design. How did you arrive at a number of 21 stakeholders? There are many details and considerations beyond simply describing "purposive sampling" that must be described to ensure the study's accuracy and transparency. Why not 30? Why not 12? Holding constant the number of stakeholders, please explain why the distribution of the expertise and practice settings of the 21 stakeholders is sufficient to justify accurate, reliable and precise themes? Are they set proportionally to the distribution of practicing pharmacists? Or is there some other rationale to deviate from this proportionality? It seems the respondents are ore heavily weighted towards policy than towards other areas, most notably community practice (where most of the surplus is occurring). For your policy maker stakeholders, what is the scope of their work related to policy making? What do they do? 5. Did anyone decline to participate as a stakeholder? Were there people excluded from participating, and on what grounds? 6. The most glaring limitation of the study is that this reviewer was not able to view the actual interview questions and structure of the interview (preface, conclusion, etc.). The details of the wording of the interview questions (including their scope of coverage, but also the neutrality or slanting of the wording of the questions) is crucial in generating information and ultimately the creation of themes. The second paragraph on page 7 should therefore be expanded substantially to include these details. 7. What was the process (which should have been identified a priori to the study's implementation) by which possible disagreements in the creation of the themes were resolved? 8. Please better and more precisely explain what you mean by "A preliminary data analysis was performed in order to identify issues that need further investigation." This is highly ambiguous and be interpreted in many ways, some of which may undercut the legitimacy of the research. I am not saying this did happen, but it should be clarified to covey to a reader that it did not happen. 9. Please explain in more detail your coding process, what words and expressions were used to identify the key concepts. Again, this is the "art" of qualitative research, and it should be described in more detail so the readers know exactly what you are trying to accomplish. 10. The second "Contributing Factors to the Oversupply" of Pharmacists in Lebanon" is superficial and needs much greater development (greater depth of analysis), as well as tied to the literature. I think what is contained in this section is fine as a starting point. But there is really no information in each subsection that would not be intuitively obvious to an individual with (even rudimentary) knowledge of the industry. It is important to not only summarize the responses, but to use them to identify novel research questions or to identify previously undiscussed policy issues. For example, the first idea and subsection discusses the clauses concept identified in the introduction. OK; certain countries use clauses to restrict supply. Is the Lebanese educational system designed to enforce clauses? What would it take to enact a clausus in terms of reform to the pharmacy educational system? Was any stakeholder able to identify what the correct number of students admitted to pharmacy school is or approximately should be? What is reported is too superficial to be of use to identifying research questions or specific directions for future policy research, which is the goal of any qualitative study. Similar types of issues pervade the remainder of this section. Since this section touches on many major themes, it is infeasible to address points of detail for each of these sections, except to note that each point, while entirely valid in premise, should be expanded with depth of analysis to ensure that the manuscript appropriately and consistently accomplishes its objectives. 11. In the Conclusions section you mention the creation of a forecasting model. I think this is a good idea. However, there are two issues that should be addressed here. First, a model should forecast with a purpose, and include forecasts that anticipate or predict the effects of specific policy responses. Other than simply forecasting graduates and current openings, what should the model specifically address as the most pressing issue? Is it the clauses, expanded scope of practice, etc.? Second, forecasting itself is not a political process. The model is built to forecast phenomena based on the needs of policy holders. The results are used to inform policy actions. But the model itself should be designed and implemented based on rigorous scientific standards, not on the consensus of politicians or stakeholders. Reviewer #2: The article is well written and establishes data to support its main points. The lack of a validated interview tool may be an important weakness to point out. The summary and analysis of the data in the results and discussion sections are clear and well explained. It is challenging to remove writer, interviewer and interviewee bias from a manuscript like this. The authors attempt to reduce this and provide information in the limitation section. Perhaps even more emphasis of this point should be attempted in the limitation section. More support could have been provided to the information about limitation of pharmacists from foreign graduates getting licensed could have been offered. Additionally, consideration of the impact/problems/issues that may result from overall more regulation should have been discussed further. Thanks for this contribution to the literature and effort to undertake such an extensive interview process with stakeholders. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
A profession in danger: Stakeholders’ perspectives on supporting the pharmacy profession in Lebanon PONE-D-20-28091R1 Dear Dr. Hijazi, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Vijayaprakash Suppiah, PhD Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors have made a very thorough and meaningful attempt to address my comments. Most of my major concerns with the manuscript have now been addressed. I comment the authors for their efforts to improve the manuscript. Reviewer #2: All of my areas of recommendation have been addressed from my first review. I support the edits and responses received to my comments. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No |
| Formally Accepted |
|
PONE-D-20-28091R1 A profession in danger: Stakeholders’ perspectives on supporting the pharmacy profession in Lebanon Dear Dr. Hijazi: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Vijayaprakash Suppiah Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .